Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer
Authors
Keywords
-
Journal
JAMA Dermatology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2022-05-25
DOI
10.1001/jamadermatol.2022.1624
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
- (2021) Christian D. Sadik et al. Frontiers in Immunology
- The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
- (2021) Hiroki Hashimoto et al. Journal of Clinical Medicine
- Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database
- (2021) Keiko Ogawa et al. CLINICAL DRUG INVESTIGATION
- A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder
- (2021) Xiaoxiao Wang et al. Case Reports in Oncology
- Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
- (2021) Se Ryeong Jang et al. JAMA Network Open
- Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes
- (2020) Caroline A. Nelson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Management of immune checkpoint inhibitor-induced bullous pemphigoid
- (2020) Zoe Apalla et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Sex-associated molecular differences for cancer immunotherapy
- (2020) Youqiong Ye et al. Nature Communications
- Immune checkpoint inhibitor–induced bullous pemphigoid: Towards a new class of drug-drug interaction?
- (2020) Marc Pujalte-Martin et al. EUROPEAN JOURNAL OF CANCER
- Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma
- (2020) Amy K. Bieber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid
- (2019) Khalaf Kridin et al. JAMA Dermatology
- A case of atezolizumab‐induced photodistributed bullous pemphigoid
- (2019) Erica Leavitt et al. Dermatologic Therapy
- Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
- (2019) Christian D. Sadik et al. Frontiers in Immunology
- Bullous Pemphigoid in a Patient Treated with Pembrolizumab
- (2019) Kanako Hara et al. INTERNAL MEDICINE
- Unknown
- (2018) INTERNATIONAL JOURNAL OF DERMATOLOGY
- Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma
- (2018) Kyle T. Amber et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Unknown
- (2018) JOURNAL OF DERMATOLOGY
- Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer
- (2018) Rohan Garje et al. JOURNAL OF IMMUNOTHERAPY
- Bullous Pemphigoid–like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab
- (2018) Amalia Anastasopoulou et al. JOURNAL OF IMMUNOTHERAPY
- Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
- (2018) Jacob Siegel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Unknown
- (2018) JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy
- (2018) Luigia Panariello et al. EUROPEAN JOURNAL OF CANCER
- Unknown
- (2018) INTERNATIONAL JOURNAL OF DERMATOLOGY
- Unknown
- (2017) JOURNAL OF DERMATOLOGY
- Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology
- (2017) J. P. Bandino et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor
- (2017) C.W. Kwon et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
- (2017) Laura Sowerby et al. JAMA Dermatology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab
- (2016) Anna J Lomax et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Unknown
- (2016) JOURNAL OF CUTANEOUS PATHOLOGY
- Unknown
- (2016) JOURNAL OF CUTANEOUS PATHOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
- (2016) Shelley J.E. Hwang et al. MELANOMA RESEARCH
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- (2016) J. Naidoo et al. Cancer Immunology Research
- Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
- (2016) Omar Hasan Ali et al. OncoImmunology
- Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
- (2016) Kristen M. Beck et al. Journal for ImmunoTherapy of Cancer
- A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
- (2015) Giuliana Carlos et al. MELANOMA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started